non-small-cell-lung-cancer

Documents about non-small-cell-lung-cancer

• Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors#836847ClinicalTrials.gov
• Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)#146457ClinicalTrials.gov
• A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies#287543ClinicalTrials.gov
• Augmenting Large Language Model With Prompt Engineering and Supervised Fine-Tuning in Non-Small Cell Lung Cancer Tumor-Node-Metastasis Staging: Framework Development and Validation.#18486NCBI PubMed Central
• TCF1+CD4+ T cells and microglia co-orchestrate tertiary lymphoid structures to enhance prognosis and immunotherapy in non-small cell lung cancer with brain metastases.#170676NCBI PubMed Central
• Detecting actionable mutations from matched plasma-based versus tissue next-generation sequencing in advanced non-small cell lung cancer: a retrospective single centre analysis on site#208776HAL (France)
• A contamination-adjusted tissue thrombopoietic framework identifies a clinically relevant CAF-myeloid niche in non-small cell lung cancer: a paired transcriptomic and survival study.#242256NCBI PubMed Central
• Prognostic associations between patient-reported outcomes and overall survival among patients with advanced squamous non-small cell lung cancer: results from the RATIONALE-307 trial.#298919NCBI PubMed Central
• In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy#312101HAL (France)
• A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies#343826ClinicalTrials.gov
• Supplemental Material for: Rapid Regression of Choroidal Metastasis Under First-Line Osimertinib Therapy in EGFR-Mutated Non–Small Cell Lung Cancer: A Case Report#436092Figshare
• SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）#444863ClinicalTrials.gov
• Prognostic value of metabolic tumor volume on [18F]FDG PET/CT in addition to the TNM classification system of locally advanced non-small cell lung cancer#644426JLUpub
• The immunological fitness of NSCLC patients drives the response to anti-PD1-based immunotherapy regardless of age#652989IRIS
• Impact of surgical approaches on prognosis in elderly patients with T4N0M0 non-small cell lung cancer: a competing risk analysis based on the SEER database.#685579NCBI PubMed Central
• Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer#805819ClinicalTrials.gov
• Natural language processing-based model to predict radiation pneumonitis in patients with locally advanced non-small cell lung cancer undergoing chemoradiotherapy: a retrospective cohort study.#823497NCBI PubMed Central
• Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation#825938ClinicalTrials.gov
• Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases#839877ClinicalTrials.gov
• Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy#126926HAL (France)
• A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.#481766ClinicalTrials.gov
• PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy#184828ClinicalTrials.gov
• A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body#804452ClinicalTrials.gov
• Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors#201781ClinicalTrials.gov
• Predictive Value of FDG-TEP During Radiotherapy or Chemo-radiotherapy in Patients With NCSC on the One-year Survival#828714ClinicalTrials.gov
• A data-driven cartography of NSCLC vaccine research: Quantifying the paradigm shift toward immuno-oncology combination therapies#4675Europe PMC
• A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC#800330ClinicalTrials.gov
• Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)#842181ClinicalTrials.gov
• The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications#350797HAL (France)
• Machine learning-based prediction and external validation of treatment-related myelosuppression in patients with non-small cell lung cancer receiving PD-1 inhibitors plus platinum-doublet chemotherapy.#685575NCBI PubMed Central
• Lymphocyte Depletion and Change in Lymphocyte Functionality#804372ClinicalTrials.gov
• Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)#807893ClinicalTrials.gov
• A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.#841935ClinicalTrials.gov
• Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors#812228ClinicalTrials.gov
• An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies#807660ClinicalTrials.gov
• Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C–mutant non-small cell lung cancer#406912Springer Nature OA
• Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression#837556ClinicalTrials.gov
• Effectiveness of mindfulness-based stress reduction in managing fatigue, anxiety, and depression among non-small cell lung cancer patients receiving surgery and adjuvant chemotherapy: A randomized controlled trial.#590NCBI PubMed Central
• Nomogram integrating MRI radiomics and white matter hyperintensity grading for predicting overall survival in patients with non-small cell lung cancer and brain metastases receiving whole-brain radiotherapy.#402596NCBI PubMed Central
• Radiomics using contrast-enhanced T1-weighted imaging and clinical features for predicting response to EGFR-TKIs in EGFR-mutated non-small cell lung cancer patients with brain metastases.#610321NCBI PubMed Central
• The extent of lymph node dissection in early-stage non-small cell lung cancer: current controversies, evidence gaps, and future directions in the immunotherapy era-a narrative review.#685614NCBI PubMed Central
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies#813349ClinicalTrials.gov
• A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy#424196ClinicalTrials.gov
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)#268024ClinicalTrials.gov
• Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC#837579ClinicalTrials.gov
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies#830569ClinicalTrials.gov
• A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors#832695ClinicalTrials.gov
• GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy#836993ClinicalTrials.gov
• First-line sugemalimab plus chemotherapy for metastatic non-small-cell lung cancer: an updated cost-effectiveness analysis based on 4-year survival data#458447Figshare
• ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)#279487ClinicalTrials.gov